NCT05512962View on ClinicalTrials.gov

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Diabetic Macular Edema
Interventions
DRUG

Triamcinolone Acetonide

Single suprachoroidal Administration of Triamcinolone acetonide

DEVICE

Semi-automated Suprachoroidal Microcatheter

Ophthalmic Adminstration Device

Trial Locations (6)

55435

Retina Consultants of Minnesota, Minneapolis

77384

Retina Consultants of Texas - The Woodlands, Houston

77401

Retina Consultants of Texas - Bellaire, Houston

78240

Retina Consultants of Texas - San Antonio, San Antonio

78705

Austin Retina Associates, Austin

93309

California Retina Consultants, Bakersfield

All Listed Sponsors
lead

Oxular Limited

INDUSTRY